1. Introduction
Cancer remains one of the leading causes of morbidity and mortality worldwide, with conventional therapies such as chemotherapy and radiotherapy often limited by systemic toxicity, off-target effects, and incomplete tumor eradication (Maeda, 2015; Grancharova et al., 2024). In recent years, nanomedicine has emerged as a promising approach to overcome these limitations by leveraging nanoscale materials to deliver therapeutic agents with high specificity, enhance diagnostic precision, and modulate the tumor microenvironment. Nanomedicine encompasses a wide range of strategies, including nanoparticles (NPs), liposomes, dendrimers, and hybrid nanostructures, designed to improve drug solubility, stability, and biodistribution while minimizing systemic toxicity (Garg et al., 2024b; Rehan et al., 2024).
Targeted drug delivery remains a cornerstone of nanomedicine-based cancer therapy. Nanoparticles can be engineered to accumulate selectively in tumor tissues via passive mechanisms, such as the enhanced permeability and retention (EPR) effect, or through active targeting using surface ligands that recognize tumor-specific receptors (Maeda et al., 2013; GARG_JCM_3466). This precision delivery not only increases the local concentration of therapeutics at tumor sites but also reduces off-target toxicity, which is a major limitation of conventional chemotherapy (Grancharova et al., 2024). Liposomal formulations, dendrimers, and polymeric nanoparticles have demonstrated significant improvements in pharmacokinetics and therapeutic index in both preclinical and clinical settings, facilitating enhanced drug accumulation and controlled release (Rehan et al., 2024; Bezbaruah et al., 2022).
Nanomedicine has also transformed the field of cancer diagnostics and imaging. Functionalized nanoparticles can serve as contrast agents for magnetic resonance imaging (MRI), computed tomography (CT), and photoacoustic imaging, allowing for early tumor detection, precise staging, and real-time monitoring of therapeutic response (Garg et al., 2024b; Rehan et al., 2024). Iron oxide nanoparticles (IONPs), in particular, provide theranostic capabilities, integrating diagnostic imaging with therapeutic functionality, enabling simultaneous tumor visualization and treatment (Grancharova et al., 2024). This dual capability, known as theranostics, enhances clinical decision-making and allows for personalized treatment adjustments, aligning with the principles of precision oncology.
Beyond traditional drug delivery and imaging, nanomedicine facilitates advanced therapeutic modalities such as photodynamic therapy (PDT) and gene therapy. Photosensitizer-loaded nanocarriers, including polymeric nanoparticles, nanoliposomes, and metal-based nanoparticles, generate reactive oxygen species under light irradiation, selectively inducing apoptosis in tumor cells while sparing surrounding healthy tissues (Rehan et al., 2024). Additionally, inorganic nanoparticles such as gold nanoparticles (AuNPs) and superparamagnetic iron oxide nanoparticles (SPIONs) have shown efficacy in gene delivery, enhancing the intracellular transfer of therapeutic nucleic acids, including siRNA and RNA aptamers, with reduced immunogenicity and cytotoxicity (Chen et al., 2016; Rehan et al., 2024).
The advent of immunotherapy has further benefited from nanomedicine-based strategies. CAR-T cell therapy, exemplified by the ZUMA-1 and JULIET trials, has shown remarkable clinical outcomes in hematologic malignancies, achieving high overall response rates and durable remissions (Garg et al., 2024a). Similarly, immune checkpoint inhibitors (ICIs), such as combinations of nivolumab with ipilimumab or pembrolizumab with chemotherapy, demonstrate enhanced survival outcomes in metastatic melanoma and non-small cell lung cancer, with nanomedicine approaches optimizing delivery and modulating immune responses (Garg et al., 2024a). Preclinical studies using nanoparticles as immunomodulatory platforms indicate improved antigen presentation, sustained immune activation, and synergistic effects when combined with conventional therapies (Debele et al., 2020; Kiaie et al., 2023).
Despite these promising results, the translation of nanomedicine from bench to bedside presents challenges. Variability in nanoparticle synthesis, differences in surface modification, and heterogeneity in tumor biology can influence therapeutic efficacy and safety profiles (Rehan et al., 2024). Regulatory considerations, manufacturing scalability, and standardized clinical protocols remain key barriers to widespread adoption. Meta-analytic assessment of existing clinical trials and preclinical studies is critical to quantify efficacy, identify sources of heterogeneity, and establish evidence-based guidelines for clinical application (Garg et al., 2024b; Rehan et al., 2024).
Nanomedicine represents a paradigm shift in cancer therapy, offering precise, multifunctional, and synergistic approaches to treatment. By integrating targeted drug delivery, advanced imaging, gene therapy, and immunotherapy, nanomedicine holds the potential to improve patient outcomes while reducing adverse effects. Systematic review and meta-analysis of current preclinical and clinical evidence underscore its efficacy and highlight areas for future research, including standardization of nanoparticle design, multicenter clinical trials, and regulatory harmonization. This comprehensive synthesis provides an evidence-based framework for the continued advancement of nanomedicine in oncology, paving the way for personalized and precision cancer therapies (Garg et al., 2024a, 2024b; Grancharova et al., 2024; Rehan et al., 2024).



